Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HBB | P68871 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dichlororibobenzimidazole SCHEMBL29352589 | 1.00 | TP53 (0.54) | TP53LMNAKDM4EPKMHDAC6 | |
| Dichlororibobenzimidazole SCHEMBL8367472 | 1.00 | TP53 (0.54) | TP53LMNAKDM4EPKMHDAC6 | |
| Dichlororibobenzimidazole SCHEMBL1535249 | 1.00 | TP53 (0.54) | TP53LMNAKDM4EPKMHDAC6 | |
| Dichlororibobenzimidazole SCHEMBL8368991 | 1.00 | TP53 (0.54) | TP53LMNAKDM4EPKMHDAC6 | |
| Dichlororibobenzimidazole SCHEMBL23815679 | 1.00 | TP53 (0.54) | TP53LMNAKDM4EPKMHDAC6 | |
| Dichlororibobenzimidazole SCHEMBL23982247 | 1.00 | TP53 (0.54) | TP53LMNAKDM4EPKMHDAC6 | |
| Dichlororibobenzimidazole SCHEMBL7812697 | 1.00 | TP53 (0.54) | TP53LMNAKDM4EPKMHDAC6 | |
| Dichlororibobenzimidazole SCHEMBL20419020 | 1.00 | TP53 (0.54) | TP53LMNAKDM4EPKMHDAC6 | |
| Dichlororibobenzimidazole SCHEMBL8368931 | 1.00 | TP53 (0.54) | TP53LMNAKDM4EPKMHDAC6 | |
| Dichlororibobenzimidazole SCHEMBL29533962 | 1.00 | TP53 (0.54) | TP53LMNAKDM4EPKMHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0420872-A4 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES | — | 1992-10-21 | — | — | EP | claimed |
| EP-0420872-A1 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES. | UNIV TEMPLE (US) | 1991-04-10 | — | — | EP | claimed |
| WO-1989012380-A2 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HI (US) | 1989-12-28 | — | — | WO | claimed |
| US-20260092931-A1 | Bcl2 Family in Dysfunctional Neurons Is Critical to the Evolution, Diagnosis and Treatment of Neurodegenerative Diseases Including but Not Limited to Corticobasal Degeneration, Chronic Traumatic Encephalopathy, Amyotrophic Lateral Sclerosis (Als), Alzheimer's Disease, Parkinson's Disease, Down's Syndrome Dementia, and Lewy Body Dementia | NUOVO GERARD (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4582100-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20250171789-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES | CureVac SE (DE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025085596-A1 | HIGH-THROUGHPUT METHODS TO IDENTIFY AND CLASSIFY MODULATORS OF NUCLEOLAR MORPHOLOGY AND FUNCTION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-119789868-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2025-04-08 | — | — | CN | disclosed |
| US-12258567-B2 | Artificial nucleic acid molecules | CureVac SE (DE) | 2025-03-25 | — | — | US | disclosed |
| US-20250051391-A1 | PEPTIDE INHIBITORS AND METHODS FOR INHIBITING PROTEIN AGGREGATION IN NEURONS AND NEURODEGENERATIVE DISEASES | UNIVERSITY HEALTH NETWORK (CA) | 2025-02-13 | — | — | US | disclosed |
| US-20240294928-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES | CureVac SE (DE) | 2024-09-05 | — | — | US | disclosed |
| US-5700785-A | ADMINISTERING TO TREAT RETROVIRAL INFECTIONS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1997-12-23 | — | — | US | disclosed |
| US-5605802-A | DETECTING LEVEL OF TYROSINE PHOSPHORYLATION OF MATRIX PROTEIN; IDENTIFYING TEST COMPOUNDS WHICH CAUSE A REDUCED LEVEL OF TYROSINE PHOSPHORYLATION | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1997-02-25 | — | — | US | disclosed |
| US-5550111-A | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0716856-A2 | Therapeutic uses of 2',5'-oligoadenylate derivatives | Temple University of the Commonwealth System of Higher Education (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1996010746-A1 | METHODS OF IDENTIFYING AGENTS WHICH BLOCK HIV INFECTION | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1996-04-11 | — | — | WO | disclosed |
| EP-0681701-A1 | METHOD OF DETECTING CARCINOMA | DANA FARBER CANCER INSTITUTE (US) | 1995-11-15 | — | — | EP | disclosed |
| WO-1994017414-A1 | METHOD OF DETECTING CARCINOMA | DANA FARBER CANCER INSTITUTE (US) | 1994-08-04 | — | — | WO | disclosed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294928-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES | NSUN3, AGO2, UPF1 | TP53 203/4885LMNA 1819/4885KDM4E 2910/4885 |
| US-20260092931-A1 | Bcl2 Family in Dysfunctional Neurons Is Critical to the Evolution, Diagnosis and Treatment of Neurodegenerative Diseases Including but Not Limited to Corticobasal Degeneration, Chronic Traumatic Encephalopathy, Amyotrophic Lateral Sclerosis (Als), Alzheimer's Disease, Parkinson's Disease, Down's Syndrome Dementia, and Lewy Body Dementia | BCL2L1, BCL2L11, BCL2L13 | TP53 42/4885LMNA 152/4885KDM4E 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.